Aracatuba Dental School, São Paulo State University, São Paulo, Brazil.
Aracatuba Dental School, São Paulo State University, São Paulo, Brazil.
J Dent. 2018 Sep;76:1-8. doi: 10.1016/j.jdent.2018.06.014. Epub 2018 Jun 27.
This systematic review and meta-analysis aimed to answer the PICO question: "Do patients who have received bone grafts with bone substitute (biomaterials) present bone gain (before implant installation), complications, and implant survival rates similar to autogenous grafts when used in the posterior mandible region?".
This review followed the PRISMA statement and has been registered at PROSPERO (CRD42016048471). Studies published in English, randomized controlled and/or prospective clinical trials with at least 10 patients, and studies that compared grafts with bone substitutes to autogenous bone grafts (split-mouth design) were included.
An electronic search and a manual search were conducted in PubMed/MEDLINE, Scopus, and Cochrane databases up to April 2018.
Our initial search yielded 640 articles; we selected four articles that met the inclusion criteria. All selected studies used a split-mouth design.
Our analysis revealed no significant difference between the biomaterial and autogenous groups in terms of bone gain (P = 0.11; mean difference [MD]: 0.59; 95% confidence interval [CI]: -0.13-1.31) or complication rate (P = 0.72; risk ratio [RR]: 1.25; 95% CI: 0.37-4.23). Sixty-six implants were installed in the biomaterial group and 63 in the autogenous group; these showed no significant difference in implant survival rate (P = 0.50; RR: 1.57; 95% CI: 0.43-5.81).
We conclude that biomaterials or autogenous bone are indicated for the reconstruction of the posterior mandibular atrophic region, without lowering implant survival.
本系统评价和荟萃分析旨在回答 PICO 问题:“在接受了含有骨替代物(生物材料)的骨移植的患者中,当在后下颌区域使用时,他们的骨增量(在植入物安装之前)、并发症和植入物存活率是否与自体移植物相似?”。
本综述遵循 PRISMA 声明,并已在 PROSPERO(CRD42016048471)上注册。纳入了发表在英文期刊上的、随机对照和/或前瞻性临床试验,且至少有 10 名患者,以及比较骨替代物与自体骨移植(分口设计)的研究。
在 PubMed/MEDLINE、Scopus 和 Cochrane 数据库中进行了电子搜索和手工搜索,截至 2018 年 4 月。
我们的初步搜索产生了 640 篇文章;我们选择了符合纳入标准的 4 篇文章。所有入选的研究均采用分口设计。
我们的分析显示,在骨增量(P=0.11;平均差异[MD]:0.59;95%置信区间[CI]:-0.13-1.31)或并发症发生率(P=0.72;风险比[RR]:1.25;95%CI:0.37-4.23)方面,生物材料组和自体组之间无显著差异。生物材料组共植入 66 枚种植体,自体组植入 63 枚种植体,两组种植体存活率无显著差异(P=0.50;RR:1.57;95%CI:0.43-5.81)。
我们的结论是,生物材料或自体骨均可用于后下颌萎缩区域的重建,不会降低植入物的存活率。